Skip to main content
Erschienen in: Journal of Cancer Education 2/2016

01.06.2016 | Editorial

In Memoriam—Richard F. Bakemeier, MD, MSc

verfasst von: Arthur Michael Michalek

Erschienen in: Journal of Cancer Education | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Excerpt

On January 31, 2016, we lost a dear friend Richard F. Bakemeier. His obituary in the Denver Post began “physician, scientist, teacher, canoeist, hiker, traveler.” To us, he was a mentor, colleague, and friend. Dick lived life to the fullest and will be remembered by many of us in many yet kindred ways. In 2010, this Journal dedicated an issue to him which contained numerous remembrances from his many colleagues within the field of cancer education [1]. This is a must read for all of us who knew Dick and for those of you who need to know him. Richard Gallagher began this tribute section by aptly characterizing him as someone who “… has played many roles including physician, teacher, scientist, mentor, leader, lobbyist, editor-in-chief, and as a persistent constructive critic of the status quo in cancer education.” As the founding editor of this Journal, he certainly was an advocate and critic. I recently spent several days reviewing his many editorials and articles in the Journal of Cancer Education. These readings brought back many memories. They gave me pause to recall my initial meetings of him and of the American Association for Cancer Education. However, I “knew” him years before I ever met him. As I cited in the tribute issue “Our relationship dates back to my graduate student days when I spent many happy hours referring to the “Orange” oncology book.” My remembrances of him then, as they are now, were that “He was always teaching… always pushing… prodding… nurturing. He not only taught us, he gave us a voice. At a time when so few journals published anything related to medical education, Dick was determined to start one…” …
Literatur
1.
Zurück zum Zitat Gallagher RE, Tributes to Richard F, Bakemeier MD (2010) J Cancer Educ 25(2):129 Gallagher RE, Tributes to Richard F, Bakemeier MD (2010) J Cancer Educ 25(2):129
3.
Zurück zum Zitat Bakemeier RF (1987) The rebirth of cancer education grants. J Cancer Educ 2(2):65–67CrossRef Bakemeier RF (1987) The rebirth of cancer education grants. J Cancer Educ 2(2):65–67CrossRef
4.
Zurück zum Zitat Bakemeier RF (1987) Frustration, deterioration, and solution. J Cancer Educ 2(3):139–140CrossRef Bakemeier RF (1987) Frustration, deterioration, and solution. J Cancer Educ 2(3):139–140CrossRef
5.
Zurück zum Zitat Bakemeier RF (1991) Is NCI, continuous infusion the only cure for cancer education dyscoordination syndrome? J Cancer Educ 6(3):111–112CrossRef Bakemeier RF (1991) Is NCI, continuous infusion the only cure for cancer education dyscoordination syndrome? J Cancer Educ 6(3):111–112CrossRef
6.
Zurück zum Zitat Bakemeier RF (1995) Ten years of the journal of cancer education. J Cancer Educ 10(4):187–190PubMed Bakemeier RF (1995) Ten years of the journal of cancer education. J Cancer Educ 10(4):187–190PubMed
7.
Zurück zum Zitat Bakemeier RF (2005) It has been fun—and a challenge! J Cancer Educ 20(4):201–202CrossRef Bakemeier RF (2005) It has been fun—and a challenge! J Cancer Educ 20(4):201–202CrossRef
Metadaten
Titel
In Memoriam—Richard F. Bakemeier, MD, MSc
verfasst von
Arthur Michael Michalek
Publikationsdatum
01.06.2016
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 2/2016
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-016-1019-0

Weitere Artikel der Ausgabe 2/2016

Journal of Cancer Education 2/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.